MY168778A - Oligonucleotide chelate complex-polypeptide compositions and methods - Google Patents
Oligonucleotide chelate complex-polypeptide compositions and methodsInfo
- Publication number
- MY168778A MY168778A MYPI2014003189A MYPI2014003189A MY168778A MY 168778 A MY168778 A MY 168778A MY PI2014003189 A MYPI2014003189 A MY PI2014003189A MY PI2014003189 A MYPI2014003189 A MY PI2014003189A MY 168778 A MY168778 A MY 168778A
- Authority
- MY
- Malaysia
- Prior art keywords
- methods
- chelate complex
- polypeptide compositions
- oligonucleotide chelate
- polypeptide
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 239000013522 chelant Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 150000004697 chelate complex Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648711P | 2012-05-18 | 2012-05-18 | |
| US201261695035P | 2012-08-30 | 2012-08-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY168778A true MY168778A (en) | 2018-12-04 |
Family
ID=49581470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2014003189A MY168778A (en) | 2012-05-18 | 2013-05-17 | Oligonucleotide chelate complex-polypeptide compositions and methods |
Country Status (34)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2158316T3 (pl) | 2007-05-11 | 2015-10-30 | Adynxx Inc | Ekspresja genowa oraz ból |
| AU2013259402B2 (en) | 2012-05-10 | 2017-12-21 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
| TWI620568B (zh) | 2012-08-30 | 2018-04-11 | 雷普利可公司 | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 |
| MX381042B (es) | 2014-07-10 | 2025-03-12 | Replicor Inc | Uso de un complejo quelato y un anàlogo de neucleòsido o neucleòtido para tratar infecciones de virus de la hepatitis b y hepatitis d. |
| EP3180434B1 (en) | 2014-08-15 | 2019-07-17 | Adynxx, Inc. | Oligonucleotide decoys for the treatment of pain |
| SG11202104636XA (en) * | 2018-11-08 | 2021-06-29 | Aligos Therapeutics Inc | S-antigen transport inhibiting oligonucleotide polymers and methods |
| US11166976B2 (en) | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| WO2024255846A1 (en) * | 2023-06-16 | 2024-12-19 | Ractigen Therapeutics | Oligonucleotide formulation |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2769114B2 (ja) * | 1993-10-29 | 1998-06-25 | サイクローン・ファーマシューティカルズ | ミニマルｂ型肝炎感染症治療用医薬組成物 |
| UA78726C2 (en) * | 2001-11-01 | 2007-04-25 | Sciclone Pharmaceuticals Inc | Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment |
| BR0314236A (pt) * | 2002-09-13 | 2005-08-09 | Replicor Inc | Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos |
| JP2006519235A (ja) | 2003-02-26 | 2006-08-24 | インターミューン インコーポレイティッド | ポリエチレングリコール修飾インターフェロン組成物およびその使用方法 |
| KR20060120162A (ko) * | 2003-10-27 | 2006-11-24 | 버텍스 파마슈티칼스 인코포레이티드 | Ｈｃｖ 치료용 배합물 |
| EP1802643A1 (en) | 2004-10-19 | 2007-07-04 | Replicor Inc. | Antiviral oligonucleotides |
| WO2007022642A2 (en) * | 2005-08-25 | 2007-03-01 | Replicor Inc. | Anti-inflammatory molecules and their uses |
| EP1928498A4 (en) * | 2005-09-29 | 2009-11-11 | Cell Biosciences Inc S | METHOD FOR THE TREATMENT OF T-CELL DISORDERS WITH TISF |
| WO2007036016A1 (en) * | 2005-09-29 | 2007-04-05 | Replicor Inc. | Therapeutic molecules and their uses |
| GB0715383D0 (en) * | 2007-08-08 | 2007-09-19 | Asterion Ltd | Interferon |
| WO2009065181A1 (en) * | 2007-11-21 | 2009-05-28 | Apollo Life Sciences Limited | Nanostructures suitable for delivery of agents |
| AU2008334948B2 (en) | 2007-12-13 | 2014-11-20 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for prevention or treatment of RSV infection |
| US8361980B2 (en) * | 2008-03-07 | 2013-01-29 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microRNA related diseases |
| CA2764683A1 (en) * | 2009-05-28 | 2010-12-02 | Joseph Collard | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
| CN102762215A (zh) * | 2009-10-16 | 2012-10-31 | 葛兰素集团有限公司 | Hbv反义抑制剂 |
| SG187165A1 (en) * | 2010-08-20 | 2013-02-28 | Replicor Inc | Oligonucleotide chelate complexes |
| TWI620568B (zh) | 2012-08-30 | 2018-04-11 | 雷普利可公司 | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 |
-
2013
- 2013-05-17 MY MYPI2014003189A patent/MY168778A/en unknown
- 2013-05-17 ES ES13791618T patent/ES2873844T3/es active Active
- 2013-05-17 TW TW102117594A patent/TWI635864B/zh not_active IP Right Cessation
- 2013-05-17 MX MX2014014021A patent/MX346239B/es active IP Right Grant
- 2013-05-17 SG SG11201407599SA patent/SG11201407599SA/en unknown
- 2013-05-17 HR HRP20210840TT patent/HRP20210840T1/hr unknown
- 2013-05-17 EA EA201401278A patent/EA035967B1/ru unknown
- 2013-05-17 KR KR1020147035252A patent/KR102068109B1/ko active Active
- 2013-05-17 SM SM20210319T patent/SMT202100319T1/it unknown
- 2013-05-17 US US13/896,510 patent/US9492506B2/en active Active
- 2013-05-17 WO PCT/CA2013/050379 patent/WO2013170386A1/en not_active Ceased
- 2013-05-17 SI SI201331881T patent/SI2849798T1/sl unknown
- 2013-05-17 BR BR112014028654A patent/BR112014028654A2/pt active Search and Examination
- 2013-05-17 AU AU2013262416A patent/AU2013262416B2/en active Active
- 2013-05-17 CA CA2873529A patent/CA2873529C/en active Active
- 2013-05-17 NZ NZ703095A patent/NZ703095A/en unknown
- 2013-05-17 PT PT137916185T patent/PT2849798T/pt unknown
- 2013-05-17 PL PL13791618T patent/PL2849798T3/pl unknown
- 2013-05-17 EP EP13791618.5A patent/EP2849798B1/en active Active
- 2013-05-17 RS RS20210674A patent/RS62030B1/sr unknown
- 2013-05-17 LT LTEP13791618.5T patent/LT2849798T/lt unknown
- 2013-05-17 CN CN201380026009.3A patent/CN104349793B/zh active Active
- 2013-05-17 HU HUE13791618A patent/HUE054875T2/hu unknown
- 2013-05-17 DK DK13791618.5T patent/DK2849798T3/da active
- 2013-05-17 JP JP2015511877A patent/JP2015517504A/ja active Pending
-
2014
- 2014-11-06 IL IL235548A patent/IL235548B/en active IP Right Grant
- 2014-11-14 PH PH12014502551A patent/PH12014502551B1/en unknown
- 2014-11-18 DO DO2014000264A patent/DOP2014000264A/es unknown
- 2014-11-18 CR CR20140527A patent/CR20140527A/es unknown
- 2014-11-18 CL CL2014003134A patent/CL2014003134A1/es unknown
- 2014-11-18 EC ECIEPI201427694A patent/ECSP14027694A/es unknown
- 2014-11-19 CO CO14254322A patent/CO7131387A2/es unknown
- 2014-11-25 ZA ZA2014/08674A patent/ZA201408674B/en unknown
-
2021
- 2021-05-31 CY CY20211100467T patent/CY1124345T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502551B1 (en) | Oligonucleotide chelate complex-polypeptide compositions and methods | |
| IN2015DN01156A (cg-RX-API-DMAC7.html) | ||
| UA115558C2 (uk) | Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань | |
| SG10201907164SA (en) | Rna containing composition for treatment of tumor diseases | |
| LT2935303T (lt) | 4'-fluor-nukleozidai, 4'-fluor-nukleotidai ir jų analogai, skirti hcv gydymui | |
| SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| NZ629996A (en) | 2’- substituted carba-nucleoside analogs for antiviral treatment | |
| PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| PH12015500724B1 (en) | 1, 2, 4-triazine derivatives for the treatment of viral infections | |
| PH12015502658A1 (en) | 3,4-dihydroisoquinolin-2 (1h)-yl compounds | |
| PH12015501609A1 (en) | Phenicol antibacterials | |
| MX2015011193A (es) | Compuestos antivirales. | |
| IN2014CN00572A (cg-RX-API-DMAC7.html) | ||
| CL2014003325A1 (es) | Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer | |
| GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
| MX2015011198A (es) | Compuestos antivirales. | |
| MX2016006906A (es) | 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas. | |
| MX2015011125A (es) | Compuestos antivirales. | |
| MX2015011126A (es) | Compuestos antivirales. | |
| CU20140133A7 (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido |